NVLT - Novelos Therapeutics, Inc.
Once again NVLT follows TooNiceStocks rating of a "buy" and reaches a intraday high of $2.23 crushing our last ROI of 56% by another 41%! For a 2 week hold yielding a possible 97% ROI! This was indeed TNS X-Mas present to all of our members. TOONICE still believes the current rally is only the beginning as their pivotal phase III is lurking around the corner in early 2010.
Update: People have to remember to ride the huge wave of buying. Nothing last forever and always take profits and let profit shares ride :)
NOVELOS THERAPEUTICS INC. "NVLT" BULLISH TREND & OUTBREAK
TOONICE believes the current rally for NVLT is only the beginning as the due diligence below will support his belief:
Key Highlights:
NVLT is in strong financial standings and well funded
Pivotal Phase III coming in early 2010
Possible buyout even before phase 3 (read full article from BMR link below)
Elemer Piros of Rodman & Ranshaw has covered NVLT with a $3 price target and Raymond Myers, at Emerging Growth Equities has a $5 price target
NVLT challenge has been to get more coverage on Wall Street and once the Phase III data comes in, of course, that won't be a problem. NVLT already knows that bulge banks that would want to initiate on us.
-NVLT does not pay for research. No fees in terms of stock or cash. Even the attention they've gotten thus far has been unsolicited.
TOONICE rates NVLT a current "BUY"
Here is an excerpt from BioMedReport's Article: "We're well funded. We are expecting this Pivotal Phase III outcome in early 2010. We have about a year's worth of funding, so the plan is that as soon as the data is out, we're going to work with a bulge investment bank - like are you familiar with the Dendreon (NASDAQ:DNDN) story?" READ FULL REPORT FROM BIOMEDREPORTS HERE
